ASTCT Submits Letter to CMS on National Coverage Decision for CAR T-cell Therapy for Cancers

On Aug. 8, ASTCT President Navneet Majhail, MD, MS, submitted a letter to the Director of Coverage and Analysis Group at the Centers for Medicare and Medicaid Services Tamara Syrek Jensen, JD. In it, Majhail lauded CMS for their Decision Memo on CAR T-cell Therapy for Cancers. From Majhail's letter: 

"The American Society for Transplantation and Cellular Therapy (ASTCT) is very pleased with the recent coverage announcement from The Centers for Medicare and Medicaid Services (CMS) in the Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG- 00451N). The Society appreciates the opportunity to work closely with the Agency on this National Coverage Determination (NCD). ASTCT is a professional membership association of more than 2,200 physicians, scientists, and other health care professionals promoting blood and marrow transplantation and cellular therapy through research, education, scholarly publication and clinical standards. The clinical teams in our society have been instrumental in developing and implementing clinical care standards and advancing cellular therapy science, including participating in trials that led to current FDA approvals for CAR T-cell therapy."

Click here to read the letter in its entirety.

Tags: policy, CMS, CAR-T, National Coverage Decision

Theme picker